Xilio Development Inc. is a forward-thinking biotechnology company based in Waltham, Massachusetts, committed to advancing immunotherapeutic strategies that bolster the immune system's capacity to combat cancer. Leveraging its proprietary platforms, Xilio is focused on developing targeted therapies that aim to enhance clinical outcomes for patients with cancer. With a robust pipeline of innovative treatments and a strategic vision to revolutionize cancer care, Xilio presents a compelling opportunity for institutional investors seeking to engage with a key player in the dynamic oncology therapeutics landscape. Show more

Location: 828 WINTER STREET, WALTHAM, MA, UNITED STATES, 02451, Waltham, MA, 02451, USA | Website: https://xiliotx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

40.18M

52 Wk Range

$0.54 - $1.70

Previous Close

$0.59

Open

$0.60

Volume

915,324

Day Range

$0.54 - $0.60

Enterprise Value

-65.27M

Cash

103.8M

Avg Qtr Burn

-17.5M

Insider Ownership

35.34%

Institutional Own.

23.32%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Vilastobart (XTX101)+ atezolizumab Details Metastatic microsatellite stable colorectal cancer (MSS CRC)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efarindodekin Alfa (XTX301) Details Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX501 Details Solid tumor/s	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX202 (monotherapy) Details Renal cell carcinoma, Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.